BioNTech SE (BNTX) Shares Outstanding: 0.24
Is BioNTech SE’s shares outstanding high or low?
BioNTech SE's shares outstanding of 0.24 is in line with its 5-year average of 0.24, near the high end of its 5-year range (0.24–0.24).
The shares outstanding for BioNTech SE (BNTX) is 0.24. It is above its 12-month average by 0.27% (0.24).
BNTX Shares Outstanding Chart
BNTX Average Shares Outstanding Chart
BNTX Current vs Average Shares Outstanding Chart
BNTX Shares Outstanding Metrics
SHARES OUTSTANDING
0.24
SHARES OUTSTANDING AVG TTM
0.24
SHARES OUTSTANDING AVG 3Y
0.24
SHARES OUTSTANDING AVG 5Y
0.24
SHARES OUTSTANDING AVG 10Y
0.23
SHARES OUTSTANDING AVG 15Y
0.23
SHARES OUTSTANDING AVG 20Y
0.23
CURRENT VS TTM AVG
+0.27%
CURRENT VS 3Y AVG
+0.08%
CURRENT VS 5Y AVG
+0.33%
CURRENT VS 10Y AVG
+3.06%
CURRENT VS 15Y AVG
+3.06%
CURRENT VS 20Y AVG
+3.06%
Share Structure
Shares Outstanding
241.70M
Float Shares
N/A
Stock Price
$86.50
Market Cap
$21.9B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 241.70M | +0.54% |
| 2024 | 240.40M | -0.08% |
| 2023 | 240.60M | -1.11% |
| 2022 | 243.30M | -0.29% |
| 2021 | 244.00M | +3.63% |
| 2020 | 235.44M | +11.32% |
| 2019 | 211.50M | -6.77% |
| 2018 | 226.86M | +0.00% |
| 2017 | 226.86M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
BioNTech SE Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Shares Outstanding FAQ
- What is the shares outstanding for BioNTech SE (BNTX)?
- The shares outstanding for BNTX stock is 0.24.
- Is BioNTech SE's shares outstanding high or low?
- BioNTech SE's shares outstanding of 0.24 is in line with its 5-year average of 0.24, near the high end of its 5-year range (0.24–0.24).
- What is the TTM average shares outstanding for BioNTech SE (BNTX)?
- The TTM average shares outstanding for BNTX stock is 0.24.
- What is the 3Y average shares outstanding for BioNTech SE (BNTX)?
- The 3Y average shares outstanding for BNTX stock is 0.24.
- What is the 5Y average shares outstanding for BioNTech SE (BNTX)?
- The 5Y average shares outstanding for BNTX stock is 0.24.
- What is the 10Y average shares outstanding for BioNTech SE (BNTX)?
- The 10Y average shares outstanding for BNTX stock is 0.23.
- What is the 15Y average shares outstanding for BioNTech SE (BNTX)?
- The 15Y average shares outstanding for BNTX stock is 0.23.
- What is the 20Y average shares outstanding for BioNTech SE (BNTX)?
- The 20Y average shares outstanding for BNTX stock is 0.23.
BioNTech SE Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 0.24 |
| 2024-12-31 | 0.24 |
| 2023-12-31 | 0.24 |
| 2022-12-31 | 0.24 |
| 2021-12-31 | 0.24 |
| 2020-12-31 | 0.24 |
| 2019-12-31 | 0.21 |
| 2018-12-31 | 0.23 |
| 2017-12-31 | 0.23 |
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin